The U.S. Food and Drug Administration (FDA) approved on Dec. 21 Uptravi (selexipag) tablets for adult patients with pulmonary arterial hypertension (PAH). According to the Agency, the drug was shown to reduce hospitalization as well as the risks of disease progression for PAH patients in clinical trial.

Uptravi is part of a class of drugs called oral IP prostacyclin receptor agonists. Common side effects include headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremities and flushing.

Read the FDA announcement. 

Keywords: Diarrhea, Disease Progression, Headache, Hospitalization, Hypertension, Myalgia, Nausea, Receptors, Epoprostenol, Tablets, United States Food and Drug Administration, Vomiting

< Back to Listings